OBJECTIVE: To understand mutations of the HBV polymerase from the level of molecule-biology and to guide reasonably antiviral therapy in clinic and predict prognosis of the patients, the gene chips were applied to detect YMDD mutations for the serum samples with HBV DNA position before antiviral therapy. METHODS: The serum samples from 150 HBV DNA positive patients non-antiviral therapy were detected by nowly advanced gene chip technique for YMDD wildtype and YVDD and/or YIDD mutations in the region of HBV polymerase. Several positive samples had been testified by gene sequences. RESULTS: Out of 150 serum samples of HBVDNA position patients tested by gene chips, 122 cases (including YMDD wildtype and mutations) were positive (81.3%), 28 cases were negative (18.7%). In 122 positive samples, 90 cases were YMDD wildtype (73.8%) (non-mutations), 28 cases were YVDD mutation (22.9%), 2 cases were YIDD mutation (1.6%), 2 cases were YVDD/YIDD double mutations (1.6%). Total mutation rate is 26.2%. Sequence analysis of 8 positive samples verified that gene chips were available. CONCLUSION: (1) Gene chip technique for the detection of mutations of the YMDD in the region of the HBV polymerase is reliable and its specificity is high. (2) Gene chips can simultaneously and quickly detect HBV YMDD wildtype and YVDD, YIDD mutations. (3) HBV YMDD mutations have existed in several patients HBV DNA position before antiviral therapy and YVDD mutation is high. YMDD wildtype and mutation strain coexist. (4) To guide reasonably antiviral therapy in clinic and make therapeutic remedy, it is necessary for HBV-infected patients before or after antiviral therapy to detect HBV YMDD mutations.
OBJECTIVE: To understand mutations of the HBV polymerase from the level of molecule-biology and to guide reasonably antiviral therapy in clinic and predict prognosis of the patients, the gene chips were applied to detect YMDD mutations for the serum samples with HBV DNA position before antiviral therapy. METHODS: The serum samples from 150 HBV DNA positive patients non-antiviral therapy were detected by nowly advanced gene chip technique for YMDD wildtype and YVDD and/or YIDD mutations in the region of HBV polymerase. Several positive samples had been testified by gene sequences. RESULTS: Out of 150 serum samples of HBVDNA position patients tested by gene chips, 122 cases (including YMDD wildtype and mutations) were positive (81.3%), 28 cases were negative (18.7%). In 122 positive samples, 90 cases were YMDD wildtype (73.8%) (non-mutations), 28 cases were YVDD mutation (22.9%), 2 cases were YIDD mutation (1.6%), 2 cases were YVDD/YIDD double mutations (1.6%). Total mutation rate is 26.2%. Sequence analysis of 8 positive samples verified that gene chips were available. CONCLUSION: (1) Gene chip technique for the detection of mutations of the YMDD in the region of the HBV polymerase is reliable and its specificity is high. (2) Gene chips can simultaneously and quickly detect HBV YMDD wildtype and YVDD, YIDD mutations. (3) HBV YMDD mutations have existed in several patients HBV DNA position before antiviral therapy and YVDD mutation is high. YMDD wildtype and mutation strain coexist. (4) To guide reasonably antiviral therapy in clinic and make therapeutic remedy, it is necessary for HBV-infectedpatients before or after antiviral therapy to detect HBV YMDD mutations.